Stockreport

Minerva Neurosciences Spotlights Roluperidone, Lays Out Confirmatory Phase 3 Timeline for Schizophrenia [Yahoo! Finance]

Minerva Neurosciences, Inc  (NERV) 
Last minerva neurosciences, inc earnings: 3/9 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.minervaneurosciences.com/investor-relations
PDF relapse Part B; first patient expected in Q2 2026 with top-line 12-week results targeted in H2 2027 and relapse data in H2 2028 Minerva is positioning roluperidone to [Read more]